Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Axsome Therapeutics Inc AXSM

Healthcare Biotechnology
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor... see more

Recent & Breaking News (NDAQ:AXSM)

Axsome Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update

GlobeNewswire August 8, 2018

Axsome Therapeutics to Report Second Quarter 2018 Financial Results on August 8, 2018

GlobeNewswire August 1, 2018

Axsome Therapeutics Announces AXS-05 Presentation at the 2018 Alzheimer’s Association International Conference

GlobeNewswire July 17, 2018

Axsome Therapeutics Initiates Phase 2 Trial of AXS-05 in Major Depressive Disorder

GlobeNewswire June 5, 2018

Axsome Therapeutics to Present Data on AXS-05 at the 2018 American Society of Clinical Psychopharmacology Annual Meeting

GlobeNewswire May 29, 2018

Axsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update

GlobeNewswire May 8, 2018

Axsome Therapeutics, Inc. to Host Earnings Call

Accesswire May 8, 2018

Axsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric Association

GlobeNewswire May 3, 2018

Axsome Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018

GlobeNewswire May 1, 2018

Axsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial Officer

GlobeNewswire April 19, 2018

Axsome Therapeutics to Participate in the Leerink Partners’ 2018 CNS Day

GlobeNewswire April 11, 2018

Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence

GlobeNewswire March 27, 2018

Axsome Therapeutics to Present at H.C. Wainwright Annual Global Life Sciences Conference

GlobeNewswire March 26, 2018

Axsome Therapeutics to Present at 17th Annual Needham Healthcare Conference

GlobeNewswire March 19, 2018

Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics

GlobeNewswire March 12, 2018

Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

GlobeNewswire March 7, 2018

Axsome Therapeutics, Inc. to Host Earnings Call

Accesswire March 7, 2018

Axsome Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018

GlobeNewswire February 28, 2018

Axsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and Dextromethorphan

GlobeNewswire February 26, 2018

Axsome Therapeutics to Present at 2018 BIO CEO & Investor Conference

GlobeNewswire February 5, 2018